About 100 guests from 36 countries met on the XVIII. MetaSystems Distributor Meeting (DM) in November to exchange experiences and to get to know new trends and developments at MetaSystems.
MetaSystems DM2019 Largest in History
Respiratory DMI Kit
Respiratory Results Now!
Direct identification of bacteria from native respiratory samples without prior culture
Hospital-acquired pneumonia (HAP) is one of the most dangerous bacterial infections. HAP often affects critically ill patients and is responsible for a significant percentage of the developing sepsis cases. To avert such adverse health effects by HAP, treatment with appropriate antibiotics must be initiated promptly. This requires rapid identification of the pneumonia causing microorganisms.
One Step Ahead
The Respiratory DMI Kit supports quick antibiotic therapy decisions as it provides identification results directly from native respiratory patient samples such as sputum, endotracheal or bronchial aspirates without prior bacterial culture.
The assay design of 12 genus and species-specific probes enables easy, precise and reproducible identification of clinically relevant pathogens associated with the development of HAP and ventilator-associated pneumonia (VAP) within 35 minutes. Slides can be read manually or automatically scanned and imaged with the Metafer DMI Scanner.
Gram negative bacteria |
Gram positive bacteria |
|---|---|
| Acinetobacter spp. | Staphylococcus spp. |
| Enterobacteriaceae | Staphylococcus aureus |
| Escherichia coli | Streptococcus spp. |
| Haemophilus influenzae | Streptococcus pneumoniae |
| Klebsiella pneumoniae | |
| Pseudomonas aeruginosa | |
| Serratia marcescens | |
| Stenotrophomonas maltophilia |
With Further Insights
Gram stains, together with rapid DMI results, provide timely, strong, reliable and cost-effective support for antibiotic selection with valuable information about the principle bacteria associated with nosocomial pneumonia (HAP / VAP). Moreover, DMI has the important advantage over other molecular diagnostics of preserving cell morphology, allowing phenotypic examination.
At Reduced Costs
Early HAP / VAP pathogen identification provides significant cost-savings potential because it supports the timely selection of appropriate antibiotics based on commonly known resistance characteristics. And the swift selection of further specific tests for identified pathogens, such as resistance assays for S. aureus, can reduce unnecessary concomitant treatment costs and saves time and resources.
| Name | Order Number | Size |
| Respiratory DMI Kit | P-7510-011-IG | The kit includes required reagents and consumables for 72 assays |
*
MetaSystems products are used in many countries worldwide. Depending on the regulations of the respective country or region, some products may not be used for clinical diagnostic use. In Europe MetaSystems products are CE labelled in-vitro diagnostics (IVD) devices. In the USA all MetaSystems products except the Ikaros karyotyping systems are intended to be used for research or inspection only.
Digitalization and Infectious Diseases: Improving patient outcome in the age of big data
Past event in Switzerland from Jan 20 to Jan 21, 2020
This conference will enhance insights of digitalization, machine learning and personalized health in infectious diseases.
ECCMID / ESCMID 2020
Upcoming Event in France from Apr 18 to Apr 21, 2020
The world’s leading experts will come together to discuss the latest developments in infectious diseases, infection control and clinical microbiology. The congress committee is preparing a comprehensive scientific programme with keynote lectures, symposia, educational and oral sessions on parallel tracks. We look forward to seeing you along with thousands of your colleagues from around the globe in Paris.
